Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by pledging a capital investment of about $1.5 billion for U.S.-based ...
Pharmaceuticals company CSL on Tuesday reported a 3% rise in first-half profit, benefiting from further growth in its main blood-plasma business. Australia-based CSL, which runs a network of ...
Hosted on MSN
Haemonetics raises 2026 guidance, projects 7%–10% organic growth ex CSL amid strong plasma and hospital performance
The company raised its full year revenue guidance to a reported decline of 1% to 4% and organic growth ex CSL of 7% to 10%. Hospital revenue growth guidance was updated to 4% to 7% (reported and ...
With pressure piling on for CSL, the Australian vaccine and plasma specialist has elected to part ways with its CEO on the eve of its latest earnings announcement. Paul McKenzie, Ph.D., who’s served ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results